Dostarlimab: A Review

Dostarlimab: A Review

Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. As determined by an FDA-approved test this i...

Full description

Bibliographic Details
Main Authors:	Bárbara Costa, Nuno Vale
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Biomolecules
Subjects:	anti-PD-1 antibody dostarlimab immunotherapy clinical trials
Online Access:	https://www.mdpi.com/2218-273X/12/8/1031

Similar Items

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
by: Sitangshu Sekhar Biswas, et al.
Published: (2023-12-01)

Dostarlimab: From preclinical investigation to drug approval and future directions
by: Carlo Maria Cicala, et al.
Published: (2023-01-01)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
by: Vanshikha Singh, et al.
Published: (2022-08-01)

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
by: Sujatha Kumar, et al.
Published: (2021-01-01)

The journey of dostarlimab: a successful weapon for cancer treatment
by: Rouchan Ali, et al.
Published: (2022-12-01)

A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
by: Xiaolong Tom Zhang, et al.
Published: (2021-11-01)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
by: Michele Bartoletti, et al.
Published: (2022-07-01)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
by: Tae-Jun Jeong, et al.
Published: (2022-12-01)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
by: Sina Marzoughi, et al.
Published: (2021-12-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01)

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
by: Gengwei Huo, et al.
Published: (2024-06-01)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
by: Maojin You, et al.
Published: (2023-09-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma
by: Sophia Gandarillas, et al.
Published: (2024-03-01)

<sup>18</sup>F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
by: Romain-David Seban, et al.
Published: (2021-07-01)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
by: Takaaki Mizuno, et al.
Published: (2022-08-01)

Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
by: Li Xu, et al.
Published: (2024-04-01)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
by: Libin Guo, et al.
Published: (2020-07-01)

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
by: Brigida Anna Maiorano, et al.
Published: (2022-04-01)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
by: Jibin Zhang, et al.
Published: (2020-01-01)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
by: Zelei Dai, et al.
Published: (2023-11-01)

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder
by: Xiaoxiao Wang, et al.
Published: (2021-06-01)

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
by: Chen Li, et al.
Published: (2023-07-01)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
by: Li Zhou, et al.
Published: (2022-05-01)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
by: Sunny Kumar, et al.
Published: (2023-07-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2021-10-01)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2022-01-01)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
by: Dawei Wu, et al.
Published: (2022-02-01)

Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
by: Lucy Guan, et al.
Published: (2023-03-01)

Tumorous IRE1α facilitates CD8+T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma
by: Yuqi Yang, et al.
Published: (2024-01-01)

Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma
by: Yanhong Chu, et al.
Published: (2022-04-01)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
by: Ester Simeone, et al.
Published: (2017-03-01)

Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials
by: Bharat Goel, et al.
Published: (2022-07-01)

Immunotherapeutic Advances for NSCLC
by: Massafra M, et al.
Published: (2021-10-01)

Cost effectiveness of immunotherapy combination therapies for endometrial cancer
by: David J. Benjamin, et al.
Published: (2024-04-01)

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy
by: Hae-Mi Kim, et al.
Published: (2024-05-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
by: Omoruyi Credit Irabor, et al.
Published: (2022-09-01)

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
by: Surui Liu, et al.
Published: (2022-07-01)